Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2023

Dosing of first patient with SBT-77-7101 for the treatment of rheumatoid arthritis expected in early 2024

SOUTH SAN FRANCISCO, Calif. & SEATTLE–(BUSINESS WIRE)–Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (T_reg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) T_reg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15^th.

“Our CAR-Treg product candidate, SBT-77-7101, is designed to target proteins that accumulate in the joints and blood of patients with RA,” said Mark D. Eisner, M.D., MPH, Chief Medical Officer of Sonoma Biotherapeutics. “Results from this study show that we can detect CAR-reactive citrullinated antigens in both synovial fluid and blood. In addition, these protein levels correlated with systemic markers of inflammation. The levels of these CAR-reactive citrullinated proteins and inflammatory markers will be further evaluated in our upcoming Phase 1 study of SBT-77-7101 in patients with RA, which is on track to commence in early 2024.”

Presentation Details

Title: Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor T_reg Therapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis

Presenting Author: Sara Charmsaz, Ph.D.

Session Type: Poster Session A

Poster Number: 0423

Session Date/Time: Sunday, November 12 from 9:00 – 11:00 AM PT

About SBT-77-7101

SBT-77-7101 is a novel autologous chimeric antigen receptor (CAR) engineered regulatory T cell (T_reg) therapy in development for the potential treatment of rheumatoid arthritis and hidradenitis suppurativa. SBT-77-7101 is designed to selectively target citrullinated proteins, which are a hallmark of many autoimmune and inflammatory diseases and are found in the inflamed disease-associated tissues of patients. Directly targeting these citrullinated proteins is intended to dampen inflammation at its source, while leveraging an autologous approach that utilizes patients’ own cells has potential to restore balance to the immune system and promote long-term immune tolerance.

About Sonoma Biotherapeutics

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (T_reg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in T_reg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable T_reg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information, visit sonomabio.com and follow on X, formerly Twitter, and LinkedIn.

Contacts

Brian Crawford

Sonoma Biotherapeutics

[email protected]
650-238-7876

Danielle Cantey

Evoke Canale

[email protected]
619-826-4657